This book attempts to describe the role of advanced glycation end-products, particularly dietary advanced glycation end-products, in the pathological expansion of adipose tissue as well as their implications in the development of obesity associated complications. The effects of advanced glycation end-products on vasculature and their pathological implications are also described, focusing on the epigenetic mechanisms (particularly that of miRNA) modulating their effects. The authors summarize the information available on the impact of hyperglycemia on the influencing factors of non-enzymatic glycosylation, the formation of advanced glycation end-products, and the role of advanced glycation end-products and their specific receptors in diabetes. The role of advanced glycation end-products to diabetic complications is examined in conjunction with the protective role of the endogenous secretory receptor for advanced glycation end-products (esRAGE) and the therapeutic interveentions that would mimic esRAGE activity. In closing, poly-L-lysine modified with advanced glycation end-products is prepared and used as an antigen to generate a single-chain fragment variable monoclonal antibody (scFv mAb) through phage display technology.